BDA
3.5.2022 21:06:05 CEST | Business Wire | Press release
The Bermuda Business Development Agency (BDA), in partnership with the Association of Bermuda Insurers and Reinsurers (ABIR) and KBRA, is pleased to welcome climate thought leaders from around the world to Bermuda for an invite-only Bermuda Climate Summit May 23-24. The event is already at capacity, but parties interested in being added to the waitlist can email bermudaclimate@bda.bm .
The inaugural Bermuda Climate Summit will consist of an opening welcome dinner on May 23, followed by a full day of discussions on May 24, including a keynote lunch, informative panel presentations, roundtables, solutions showcase, networking opportunities, and a cocktail reception.
David Hart, BDA CEO said, “As the world’s risk capital, Bermuda is in a prime position to leverage its strengths in (re)insurance, Insurance-Linked Securities (ILS), and professional services to become the preeminent leader in climate risk finance and combat the greatest challenge of our time – climate change. Bermuda is already home to many of the world’s leading experts on weather-related catastrophes and has been working in the property catastrophe reinsurance market for decades. We are honoured to welcome global leaders to Bermuda for this extraordinary event to network, share ideas, and discuss vital solutions to the global climate crisis.”
The Hon. Walter Roban, JP, MP, Deputy Premier of Bermuda and Jim Nadler, President & CEO, KBRA will kick off proceedings by discussing Bermuda’s work in climate risk finance and how an increase in this type of financing can help mitigate against the worst effects of climate change, the benefits that innovative new technologies bring, and what a new climate finance economic pillar for Bermuda might look like.
Then John Huff, ABIR President & CEO, will moderate a panel on building resiliency in the face of climate change. Panelists include Bronwyn Claire, Senior Programme Manager, ClimateWise, Cambridge Institute for Sustainability Leadership (CISL), University of Cambridge; Ekhosuehi Iyahen, Secretary General, Insurance Development Forum; Abhisheik Dhawan, Sustainable Finance & Partnership Specialist/Corporate Lead on Climate Change, United Nations Capital Developments Fund (UNCDF); and Steven E Seitz, Director, Federal Insurance Office US Department of the Treasury.
Additional sessions will feature discussions about applied technology innovations to discuss the scale and nature of our current and anticipated climate challenges, an executive-level discussion on the growing importance of ESG and its intersection with (re)insurance and investing, and how the development of specialty financing products within the (re)insurance industry can help address climate change amid increasing consumer and regulatory pressure for climate risk management.
Guests will stay at the exclusive Rosewood Bermuda located on the shimmering waters of Bermuda’s Castle Harbour. They and their families can stay for the Bermuda Day holiday weekend to enjoy the luxury facilities and Bermuda’s many amenities including walking nature tours, twizzy tours, golf, deep-sea fishing, cave adventures, a VIP Bermuda Institute of Ocean Sciences (BIOS) tour, or a Nonsuch Island expedition. Click here to visit the BDA website for special rates and hotel information, including at the Hamilton Princess & Beach Club, conveniently located near the city of Hamilton.
The BDA thanks sponsors of Bermuda Climate Summit for their commitment to Bermuda. These include:
Partner level sponsors
- ABIR
- KBRA
Platinum sponsor
- Conduit Re
Gold sponsor
- Belco
Silver sponsor
- Aspen Re
Lanyard sponsor
- AXA XL
Beverage station sponsor
- Deloitte
Bronze sponsors
- Nephila
- HSBC Bermuda
Supporting sponsors
- Elbow Beach Capital
- Hub Culture
- KPMG
Media partner
- Bermuda Re + ILS
Click here to learn more about the BDA.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006192/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom